Silodosin API

Name	Silodosin
Chinese name	赛洛多辛/西洛多辛
Cas Number	160970-54-7
Source	India
Qualifications	USDMF/-/-/-/-

Silodosin is a new drug applied by Watson to improve symptoms caused by benign prostatic hyperplasia (BHP). The US FDA approved it for marketing on October 10, 2008. Drugs for the treatment of BPH are mainly divided into two categories, 5α-reductase inhibitors and α-receptor blockers. The representative drug of the third-generation highly selective α1-receptor blocker is tamsulosin, which has high selectivity and only acts on α1A-receptors, and on α1A-receptors in the urethra, bladder neck and smooth muscle of the prostate It has a highly selective blocking effect and relaxes the smooth muscle of the prostate, thereby improving symptoms such as dysuria caused by benign prostatic hyperplasia. After taking the patient, the adverse reaction of vertebral artery type cervical spondylosis (CVS) is much smaller. Sirodosine, as a highly selective α1A-adrenergic receptor antagonist, has obvious advantages in improving lower urinary tract symptoms and patients with benign prostatic hyperplasia compared with tamsulosin, and is more selective for the urethra than tamsulosin Rosin is 7.5 times higher and has lower side effects. It may become its substitute in the future.

Hot Tags: silodosin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lapatinib Ditosylate API, Fulvestrant API, Tavaborol API, Rasagiline Mesylate API, Paliperidone API, Idebenone API

• Previous: Obeticholic Acid API
• Next: Nalmefene Hydrochloride API